Yes. So the key thing to understand is we have not repeat and underscore not tapped the line of credit. So what you got to look at, again, and I keep going on about this, and people are sick of hearing me talking about it. But what you can look at is, is the working capital that we've described in the past. If you look at our inventory position, if you look at our WIP [ph] if you look at our vendor prepayments, if you look at our AR, for example, to a perfect example, at 12/31 of '22, we announced $1.7 million cash on the balance sheet. But if you look directly below that, there's other $4-plus million in AR and as I say, we get paid, and we often get paid in less than 30 days. So you shouldn't be surprised to see an increase in cash in this way because it's just -- it's -- if we have all our inventory. And if we have all the AR, and we have all those other things like that, we're going to convert inventory into product. We're going to convert WIP [ph] into product. We're going to sell it. We're going to get paid. We don't have any -- I'm looking at catheter on have any bad debt at all; so we're going to get it. So that's what you're looking at there, basically. It's just what we said last quarter that people should not get too hung up on the cash number. They should be looking at our inventory, work in progress, AR and all those other things, obviously, net of AP and other stuff as well to get a fuller understanding. And as I've just announced, we are approximately $13 million in working capital right now. And that, at the end of the day, that converts to cash for us and usually fairly quickly. So that's why we're able to do that. The net loss is another thing. And of course, it does contribute to it, but to a lesser and lesser extent, the more product we produce and certainly now that we're gross profit, profitable.